Uveitis is the inflammation of uvea which consists of the iris, ciliary body, and choroid. Uveitis affects approximately 3 million patients in China with ~60% classified as NIAU. Uveitis may recur ...

VivaVision Biotech (VivaVision), a clinical-stage, privately held biotechnology company focused on developing innovative treatments for ocular diseases, today announced positive topline results from ...

VVN461, a dual JAK1/TYK2 inhibitor as a non-steroidal anti-inflammatory agent, has met primary endpoints, demonstrating non-inferior efficacy compared to the standard therapy, prednisolone acetate ...

Heterochromia is a phenomenon that occurs when a person's irises are different colors. This condition is not particularly common. In fact, heterochromia can be partial, meaning tha ...

VVN461, a dual JAK1/TYK2 inhibitor as a non-steroidal anti-inflammatory agent, has met primary endpoints, demonstrating non-inferior efficacy compared to the standard therapy, prednisolone acetate (PA ...

VivaVision plans discussions with Chinese CDE and FDA for phase 3 trials, aiming to provide a non-steroidal treatment option for uveitis. VivaVision Biotech has announced the positive topline results ...

Int Ophthalmol Clin. 2015;55(3):111-131.

Join MIMS now and pay nothing for the first 30 days Join GPOnline now and pay nothing for the first 30 days ...

Authors defined metabolic syndrome as “the set of factors that increase the risk of cardiovascular disease and diabetes, such as hypertension, central obesity, insulin resistance, and atherogenic ...